Long-term safety and effectiveness of XH-S003 for PNH
Part of Blood & lymphatic clinical trials.
This study tests if the drug XH-S003 is safe and works well over a long period for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease. If you've already taken XH-S003 in a past study and your doctor thinks it helped, you may join to keep getting the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous study of XH-S003 and finished it.
- You must have gotten vaccines for meningitis and pneumonia as required by the earlier study.
- You cannot have had cancer in the last 5 years (except some minor skin or cervical cancers).
- You cannot have had a bone marrow or organ transplant, or had your spleen removed.
- You must not have serious heart, lung, liver, kidney, or blood problems, or a history of meningitis infection.
- You cannot be pregnant, breastfeeding, or have a weak immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (MY008211A) for people with paroxysmal nocturnal hemoglobinuria (PNH) who still have low red blood cell counts (anemia) even after taking anti-C5 antibody therapy. The goal is to see if this new drug can raise hemoglobin levels and improve energy.
This trial is testing a new pill (FXS6837) compared to the standard IV medicine eculizumab for people with PNH. The study lasts 24 weeks and aims to see if the new pill works better or as well and has fewer side effects.
This study tests a new oral medication called NTQ5082 for people with PNH who have not been treated with a complement inhibitor before. It aims to see if the drug can reduce the breakdown of red blood cells and improve anemia.
This study is for people with paroxysmal nocturnal hemoglobinuria (PNH) who have already taken the experimental drug HSK39297. It checks the long-term safety of continuing the treatment and makes sure it is still helpful.
This trial is for people who have already completed the Phase 2 study of LP-005 and may continue receiving it. It checks how safe and effective the drug is over a longer period.
This trial tests a new drug, HS-10542, for people with PNH who are already on a C5 inhibitor like eculizumab or covalizumab but still have low hemoglobin or need transfusions. It aims to see if this additional treatment can improve blood counts and reduce transfusion needs.
Hear when a new Paroxysmal Nocturnal Hemoglobinuria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.